Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Deals

Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics

Fineline Cube Nov 14, 2023

Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led...

Company Deals

AnchorDx Medical Partners with DiaCarta for Global Molecular Diagnostics Development

Fineline Cube Nov 14, 2023

AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing based in China, has entered...

Company

Sisram Medical Ltd Expands Asia-Pacific Presence with New Direct Sales Office in Japan

Fineline Cube Nov 14, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company that is part of the Fosun Pharmaceutical...

Company Deals

Beijing-Based Immupeutics Medicine Secures Tens of Millions in Pre-Series A+ Financing

Fineline Cube Nov 14, 2023

Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens...

Company Drug

Servier’s Tibsovo Receives FDA Approval for IDH1-Mutated R/R MDS, Expanding Indications

Fineline Cube Nov 14, 2023

France-based pharmaceutical company Servier has announced that the US Food and Drug Administration (FDA) has...

Company Drug

Huadong Medicine’s Arcalyst (Rilonacept) Filing for CAPSs Accepted by China’s NMPA

Fineline Cube Nov 14, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that the National...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ HR20031 Accepted for Review by China’s NMPA for Type 2 Diabetes

Fineline Cube Nov 14, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading Chinese pharmaceutical company, has announced that the National...

Company Drug

AstraZeneca’s Imfinzi Gains NMPA Approval for First-Line Cholangiocarcinoma Treatment

Fineline Cube Nov 14, 2023

The National Medical Products Administration (NMPA) of China has indicated on its website that it...

Company Drug

Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials

Fineline Cube Nov 13, 2023

Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug,...

Company Deals

Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE

Fineline Cube Nov 13, 2023

Among the series of deals secured by multinational corporations at the 6th China International Import...

Company Deals

Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology

Fineline Cube Nov 13, 2023

Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration...

Company Deals

Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent

Fineline Cube Nov 13, 2023

On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans...

Company Drug

Novo Nordisk Commits Over DKK 42 Billion to Expand Chronic Disease Production in Denmark

Fineline Cube Nov 13, 2023

Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, last week announced a substantial plan to...

Company

Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons

Fineline Cube Nov 13, 2023

It has been reported that Benjamin L. Basil, the current president and general manager of...

Company Drug

Clinical Research on rAAV Gene Drug ZS805 for Fabry Disease Launched by Zhishan Weixin

Fineline Cube Nov 13, 2023

Zhishan Weixin Biotechnology Co., Ltd, a China-based biotech company, has announced the launch of the...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Subsidiary Shengdi Pharmaceuticals Receives NMPA Approval for HRS-9057

Fineline Cube Nov 13, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that its...

Company Drug

Beijing Aosaikang’s Combo Therapy for NSCLC Accepted for Clinical Trial by NMPA

Fineline Cube Nov 13, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...

Company

Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters

Fineline Cube Nov 13, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the...

Company

Sandoz Invests in New Biosimilars and Penicillin API Production Sites in Europe

Fineline Cube Nov 13, 2023

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced the opening of two new production sites...

Company

Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments

Fineline Cube Nov 10, 2023

Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023,...

Posts pagination

1 … 471 472 473 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.